CN105037251A - 一种3,5-二甲基吡啶的提纯方法 - Google Patents

一种3,5-二甲基吡啶的提纯方法 Download PDF

Info

Publication number
CN105037251A
CN105037251A CN201510267462.4A CN201510267462A CN105037251A CN 105037251 A CN105037251 A CN 105037251A CN 201510267462 A CN201510267462 A CN 201510267462A CN 105037251 A CN105037251 A CN 105037251A
Authority
CN
China
Prior art keywords
lutidine
water
content
purification
water vapor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510267462.4A
Other languages
English (en)
Other versions
CN105037251B (zh
Inventor
薛谊
岳瑞宽
蒋剑华
陈洪龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Red Sun Biological Chemical Co., Ltd.
Nanjing Redsun Co., Ltd.
Original Assignee
NANJING RED SUN BIOLOGICAL CHEMICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NANJING RED SUN BIOLOGICAL CHEMICAL CO Ltd filed Critical NANJING RED SUN BIOLOGICAL CHEMICAL CO Ltd
Priority to CN201510267462.4A priority Critical patent/CN105037251B/zh
Publication of CN105037251A publication Critical patent/CN105037251A/zh
Application granted granted Critical
Publication of CN105037251B publication Critical patent/CN105037251B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127Preparation from compounds containing pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明公开了一种3,5-二甲基吡啶的提纯方法,包括以下步骤:(a)、将3,5-二甲基吡啶粗品、水、氧化剂混合,升温至回流温度回流30~80min;(b)、往步骤(a)氧化后的混合液中加入水,进行水蒸汽共沸蒸馏,收集水蒸液,至水蒸汽共沸蒸馏后余下的液体中3,5-二甲基吡啶的含量<5%,停止水蒸汽共沸蒸馏;(c)、步骤(b)得到的水蒸液分液,得到有机相和水相,有机相精馏得到脱水的3,5-二甲基吡啶成品。本发明方法操作简单、耗能少,采用氧化法将通过精馏无法除去的杂质氧化掉,通过水蒸汽共沸蒸馏、分液、精馏操作得到纯度≥99.0%的3,5-二甲基吡啶,以3,5-二甲基吡啶粗品计,收率≥85%。

Description

一种3,5-二甲基吡啶的提纯方法
技术领域
本发明属于化学领域,具体涉及一种3,5-二甲基吡啶的提纯方法。
背景技术
通常将吡啶及其衍生物统称为吡啶碱类,工业上制取吡啶及吡啶衍生物一般通过醛(酮)-氨法,统称奇奇巴宾反应,通过氨、醛或酮气相环化缩合,生成吡啶类化合物。对于这个反应的探索开始于19世纪,对其详尽的研究由奇奇巴宾在20世纪的前半叶进行,20世纪50年代开始工业生产。
气相下,乙醛、甲醛与氨反应,主要产物为吡啶及3-甲基吡啶,催化剂现多用晶型硅铝酸盐,尤其是具有一定约束指数的沸石。通过改变反应物的配比可以得到其他烷基吡啶衍生物。吡啶的衍生物中如2-甲基吡啶、2,3-二甲基吡啶、3,5-二甲基吡啶、2,3,5-三甲基吡啶等是重要的化工中间体,如3,5-二甲基吡啶是抗胃溃疡药奥美拉唑的主要中间体,通过一定的方法从吡啶底料中回收提纯能产生很高的经济效益。
发明内容
本发明的目的在于提供一种3,5-二甲基吡啶的提纯方法,采用氧化法将无法通过精馏除去的杂质氧化掉,根据烷基吡啶一般能与水共沸的特性,通过水蒸汽共沸蒸馏、分液、精馏操作得到高纯度的3,5-二甲基吡啶。
本发明的目的是通过以下措施实现的:
一种3,5-二甲基吡啶的提纯方法,包括以下步骤:
(a)、将3,5-二甲基吡啶粗品、水、氧化剂混合,升温至回流温度回流20~80min,氧化反应除去杂质;
(b)、往步骤(a)氧化后的混合液中加入水,使水的总量和3,5-二甲基吡啶粗品的重量比为2~3:1,进行水蒸汽共沸蒸馏,收集水蒸液,至水蒸汽共沸蒸馏后余下的液体中3,5-二甲基吡啶的含量<5%,停止水蒸汽共沸蒸馏;
(c)、步骤(b)得到的水蒸液分液,得到有机相和水相,有机相精馏得到脱水的3,5-二甲基吡啶成品。
步骤(a)中,所述的3,5-二甲基吡啶粗品中3,5-二甲基吡啶含量在95~97.5%之间,3,5-二甲基吡啶和水分的总含量≥98.5%。所述的3,5-二甲基吡啶粗品、水和氧化剂的重量比为100:20~40:3~8,优选为100:20~25:3~5。所述的氧化剂为高锰酸钾。
所述的3,5-二甲基吡啶粗品中还含有2,3-二甲基吡啶、2,3,5-三甲基吡啶等杂质,这类杂质由于和3,5-二甲基吡啶结构接近,无法通过精馏除去,如果3,5-二甲基吡啶粗品不进行提纯处理,达不到制药行业要求的中间体的纯度要求。在氧化过程中,3,5-二甲基吡啶粗品中的杂质2,3-二甲基吡啶、2,3,5-三甲基吡啶等杂质被高锰酸钾氧化成高沸点且不与水共沸的单吡啶酸或多吡啶酸;极小部分3,5-二甲基吡啶被氧化成3,5-吡啶二甲酸,但是控制好3,5-二甲基吡啶粗品、水、氧化剂的重量比,能够确保3,5-二甲基吡啶最后的收率≥85%。
根据添加水的量不同,回流温度不同,步骤(a)中所述的回流温度为95~110℃,优选为98~102℃;所述的回流时间优选为30~50min。
步骤(b)中,水蒸汽共沸蒸馏的终点为水蒸后余下的液体中3,5-二甲基吡啶的含量<5%。
步骤(c)中,所述的有机相中3,5-二甲基吡啶的含量在60~70%,水的含量在30~40%。
步骤(c)中,用气谱检测所述的有机相中3,5-二甲基吡啶的纯度≥99%。
步骤(c)中,所述的水相中3,5-二甲基吡啶的含量在1~5%;所述的水相回收后套用至步骤(a)中3,5-二甲基吡啶粗品的氧化反应除去杂质和步骤(b)中水蒸汽共沸蒸馏。
本发明的有益效果:
本发明方法操作简单、耗能少,采用氧化法将通过精馏无法除去的杂质氧化掉,通过水蒸汽共沸蒸馏、分液、精馏操作得到纯度≥99.0%的3,5-二甲基吡啶,以3,5-二甲基吡啶粗品(3,5-二甲基吡啶和水分的总含量≥98.5%)计,收率≥85%。
具体实施方式
实施例1
将200g3,5-二甲基吡啶粗品(水分:1.73%,3,5-二甲基吡啶:97.12%;下同)、40g水、8g高锰酸钾加入到四口瓶中升温至回流温度,搅拌回流30min,氧化反应除去杂质;往氧化后的混合液中加水550g,进行水蒸汽共沸蒸馏,收集水蒸液,水蒸结束后(四口瓶内3,5-二甲基吡啶的含量小于5%即可停止),水蒸液分液,检测上层有机相250g液体中3,5-二甲基吡啶含量65%、水含量35%;下层水相496g液体中3,5-二甲基吡啶的含量2%,回收套用至下次3,5-二甲基吡啶粗品的氧化反应除去杂质和水蒸汽共沸蒸馏。
再向四口瓶中加入200g3,5-二甲基吡啶粗品,第一批回收的水相50g,高锰酸钾8g,升温至回流温度搅拌回流30min,进行氧化反应;往氧化后的混合液中加入第一批回收的水相446g,并补加新水使水总量达550g,进行水蒸汽共沸蒸馏,收集水蒸液,水蒸结束后(四口瓶内3,5-二甲基吡啶的含量小于5%即可停止),水蒸液分液,检测上层有机相255g中3,5-二甲基吡啶含量68%、水含量32%;下层水相461g中3,5-二甲基吡啶的含量3%,回收套用至下次3,5-二甲基吡啶粗品的氧化反应除去杂质和水蒸汽共沸蒸馏。
继续向四口瓶中加入200g3,5-二甲基吡啶粗品,第二批回收的水相50g,高锰酸钾8g,升温至回流温度搅拌回流30min,进行氧化反应;加第二批回收的水相411g,并补加水使水总量达550g,进行水蒸汽共沸蒸馏,收集水蒸液,水蒸至四口瓶内3,5-二甲基吡啶含量小于等于1%后止,水蒸液分液,检测有机相310g中3,5-二甲基吡啶含量60%、水含量34%。
合并上述三次有机相,经精馏塔精馏脱水得3,5-二甲基吡啶成品508g,用气谱检测其纯度为99.3%,水分0.3%。3,5-二甲基吡啶的最终收率为86.6%。
实施例2
将410g3,5-二甲基吡啶粗品(水分:1.73%,3,5-二甲基吡啶:97.12%,下同),82g水,15g高锰酸钾加入到四口瓶中升温至回流温度,搅拌回流30min,氧化反应除去杂质;往氧化后的混合液中加水1100g,进行水蒸汽共沸蒸馏,收集水蒸液,水蒸结束后(四口瓶内3,5-二甲基吡啶的含量小于5%即可停止),水蒸液分液,检测上层有机相545g中3,5-二甲基吡啶含量68%、水含量32%,下层水相952g中3,5-二甲基吡啶的含量2.8%,回收套用至下次3,5-二甲基吡啶粗品的氧化反应除去杂质和水蒸汽共沸蒸馏。
再向四口瓶中加入400g3,5-二甲基吡啶粗品,第一批回收的水相85g,高锰酸钾15g,升温至回流温度搅拌回流30min,进行氧化反应;往氧化后的混合液中加第一批回收的水相867g,并补加水使水总量达1100g,进行水蒸汽共沸蒸馏,收集水蒸液;水蒸结束后(四口瓶内3,5-二甲基吡啶的含量小于5%即可停止),水蒸液分液,检测上层有机相490g中3,5-二甲基吡啶含量70%、水含量30%;下层水相920g中3,5-二甲基吡啶的含量5%,回收套用至下次3,5-二甲基吡啶粗品的氧化反应除去杂质和水蒸汽共沸蒸馏。
继续向四口瓶中加入415g3,5-二甲基吡啶粗品,第二批回收的水相90g,高锰酸钾16g,升温至回流温度回流搅拌30min进行氧化反应;往氧化后的混合液加第二批回收的水相830g,并补加水使水总量达1200g,进行水蒸汽共沸蒸馏,收集水蒸液;水蒸至四口瓶内3,5-二甲基吡啶含量小于等于1%后止,水蒸液分液,检测上层有机相512g中3,5-二甲基吡啶含量68%、水含量32%。
合并上述三次有机相,经精馏塔精馏脱水得3,5-二甲基吡啶成品1044g,用气谱检测其纯度为99.2%,水分0.2%。3,5-二甲基吡啶的最终收率为87.0%。
实施例3
将620g3,5-二甲基吡啶粗品(水分:1.73%,3,5-二甲基吡啶:97.12%,下同),124g水,25g高锰酸钾加入到四口瓶中升温至回流温度,搅拌回流50min,氧化反应除去杂质;往氧化后的混合液中加水1600g,进行水蒸汽共沸蒸馏,收集水蒸液;水蒸结束后(四口瓶内3,5-二甲基吡啶的含量小于5%即可停止),水蒸液分液,检测上层有机相815g中3,5-二甲基吡啶含量64%、水含量36%;下层水相1190g中3,5-二甲基吡啶的含量2%,回收套用至下次3,5-二甲基吡啶粗品的氧化反应除去杂质和水蒸汽共沸蒸馏。
再向四口瓶中加入610g3,5-二甲基吡啶粗品,第一批回收的水相130g,高锰酸钾24g,升温至回流温度搅拌回流50min,进行氧化反应;往氧化后的混合液中加第一批回收的水相1060g,并补加水使总水量达1600g,进行水蒸汽共沸蒸馏,收集水蒸液;水蒸结束后(四口瓶内3,5-二甲基吡啶的含量小于5%即可停止),水蒸液分液,检测上层有机相790g中3,5-二甲基吡啶含量68%、水含量32%;下层水相1050中3,5-二甲基吡啶的含量2%,回收套用至下次水蒸汽共沸蒸馏。
继续向四口瓶中加入600g3,5-二甲基吡啶粗品,第二批回收的水相150g,高锰酸钾24g,升温至回流温度搅拌回流50min进行氧化反应;往氧化后的混合液中后加第二批回收的水相900g,并补加水使总水量达1600g,进行水蒸汽共沸蒸馏,收集水蒸液;水蒸至四口瓶内3,5-二甲基吡啶含量小于等于1%后止,水蒸液分液,检测上层有机相891g中3,5-二甲基吡啶含量65%、水含量35%。
合并上述三次有机相,经精馏塔精馏脱水得3,5-二甲基吡啶成品1537g,用气谱检测其纯度为99.5%,水分0.3%。3,5-二甲基吡啶的最终收率为86.0%。

Claims (9)

1.一种3,5-二甲基吡啶的提纯方法,其特征在于包括以下步骤:
(a)、将3,5-二甲基吡啶粗品、水、氧化剂混合,升温至回流温度回流20~80min,氧化反应除去杂质;
(b)、往步骤(a)氧化后的混合液中加入水,使水的总量和3,5-二甲基吡啶粗品的重量比为2~3:1,进行水蒸汽共沸蒸馏,收集水蒸液,至水蒸汽共沸蒸馏后余下的液体中3,5-二甲基吡啶的含量<5%,停止水蒸汽共沸蒸馏;
(c)、步骤(b)得到的水蒸液分液,得到有机相和水相,有机相精馏得到脱水的3,5-二甲基吡啶成品。
2.根据权利要求1所述的3,5-二甲基吡啶的提纯方法,其特征在所述的3,5-二甲基吡啶粗品中3,5-二甲基吡啶和水分的总含量≥98.5%。
3.根据权利要求1所述的3,5-二甲基吡啶的提纯方法,其特征在于步骤(a)中,所述的3,5-二甲基吡啶粗品、水、氧化剂的重量比为100:20~40:3~8。
4.根据权利要求3所述的3,5-二甲基吡啶的提纯方法,其特征在于步骤(a)中,所述的3,5-二甲基吡啶粗品、水、氧化剂的重量比为100:20~25:3~5。
5.根据权利要求1、3或4所述的3,5-二甲基吡啶的提纯方法,其特征在于所述的氧化剂为高锰酸钾。
6.根据权利要求1所述的3,5-二甲基吡啶的提纯方法,其特征在于步骤(a)中,所述的回流时间为30~50min。
7.根据权利要求1所述的3,5-二甲基吡啶的提纯方法,其特征在于步骤(c)中,所述的有机相中3,5-二甲基吡啶的含量在60~70%,水的含量在30~40%。
8.根据权利要求1或5所述的3,5-二甲基吡啶的提纯方法,其特征在于步骤(c)中,所述的有机相中3,5-二甲基吡啶的纯度≥99%。
9.根据权利要求1所述的3,5-二甲基吡啶的提纯方法,其特征在于步骤(c)中,所述的水相中3,5-二甲基吡啶的含量在1~5%;所述的水相回收后套用至步骤(a)中3,5-二甲基吡啶粗品的氧化反应除去杂质和步骤(b)中水蒸汽共沸蒸馏。
CN201510267462.4A 2015-05-22 2015-05-22 一种3,5‑二甲基吡啶的提纯方法 Active CN105037251B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510267462.4A CN105037251B (zh) 2015-05-22 2015-05-22 一种3,5‑二甲基吡啶的提纯方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510267462.4A CN105037251B (zh) 2015-05-22 2015-05-22 一种3,5‑二甲基吡啶的提纯方法

Publications (2)

Publication Number Publication Date
CN105037251A true CN105037251A (zh) 2015-11-11
CN105037251B CN105037251B (zh) 2017-07-18

Family

ID=54444292

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510267462.4A Active CN105037251B (zh) 2015-05-22 2015-05-22 一种3,5‑二甲基吡啶的提纯方法

Country Status (1)

Country Link
CN (1) CN105037251B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107382830A (zh) * 2017-08-17 2017-11-24 滨海金海立医药化工有限公司 一种拉唑生产中吡啶衍生物的分离方法
CN109608389A (zh) * 2019-01-24 2019-04-12 安徽国星生物化学有限公司 一种高纯度3,5-二甲基吡啶提纯分离工艺

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB561723A (en) * 1942-03-25 1944-06-01 Reilly Tar & Chem Corp Process of purifying 3-picoline
GB563273A (en) * 1941-05-31 1944-08-08 Reilly Tar & Chem Corp Improvements in or relating to method of purifying 3-picoline
GB580048A (en) * 1943-04-28 1946-08-26 Reilly Tar & Chem Corp A distillation process for separating 3-picoline, 4-picoline, and 2, 6-lutidine
US2516370A (en) * 1950-07-25 Beta-picolines
CS163586B1 (en) * 1973-04-30 1975-08-29 Jan Vymetal Method of 3,5-dimethylpyridine winning
JPS60214775A (ja) * 1984-04-04 1985-10-28 Koei Chem Co Ltd 3−ピコリンの分離法
CN101066946A (zh) * 2007-06-01 2007-11-07 华东理工大学 一种甲基吡啶混合物的分离方法
CN101337923A (zh) * 2008-08-29 2009-01-07 南京第一农药集团有限公司 一种粗吡啶的提纯方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2516370A (en) * 1950-07-25 Beta-picolines
GB563273A (en) * 1941-05-31 1944-08-08 Reilly Tar & Chem Corp Improvements in or relating to method of purifying 3-picoline
GB561723A (en) * 1942-03-25 1944-06-01 Reilly Tar & Chem Corp Process of purifying 3-picoline
GB580048A (en) * 1943-04-28 1946-08-26 Reilly Tar & Chem Corp A distillation process for separating 3-picoline, 4-picoline, and 2, 6-lutidine
CS163586B1 (en) * 1973-04-30 1975-08-29 Jan Vymetal Method of 3,5-dimethylpyridine winning
JPS60214775A (ja) * 1984-04-04 1985-10-28 Koei Chem Co Ltd 3−ピコリンの分離法
CN101066946A (zh) * 2007-06-01 2007-11-07 华东理工大学 一种甲基吡啶混合物的分离方法
CN101337923A (zh) * 2008-08-29 2009-01-07 南京第一农药集团有限公司 一种粗吡啶的提纯方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COULSON, E. A.等: "Coal-tar bases. VI. Synthesis of 3,5-lutidine", 《JOURNAL OF THE CHEMICAL SOCIETY》 *
COULSON, E. A.等: "Preparation and physical properties of the pure lutidines", 《JOURNAL OF THE CHEMICAL SOCIETY》 *
傅伍尧等: "混合甲基吡啶的分离及由3-甲基吡啶制备於酸", 《化学世界》 *
张楠等: "附载型高锰酸钾/三氧化二铝对2,6-二甲基吡啶选择氧化的研究", 《广东化工》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107382830A (zh) * 2017-08-17 2017-11-24 滨海金海立医药化工有限公司 一种拉唑生产中吡啶衍生物的分离方法
CN107382830B (zh) * 2017-08-17 2019-10-29 滨海金海立医药化工有限公司 一种拉唑生产中吡啶衍生物的分离方法
CN109608389A (zh) * 2019-01-24 2019-04-12 安徽国星生物化学有限公司 一种高纯度3,5-二甲基吡啶提纯分离工艺

Also Published As

Publication number Publication date
CN105037251B (zh) 2017-07-18

Similar Documents

Publication Publication Date Title
CN103880783B (zh) 反应控制相转移催化剂催化丙烯环氧化制备环氧丙烷方法
CN101648907B (zh) 2-氯甲基-4-甲氧基-3,5-二甲基吡啶盐酸盐的纯化方法
US9643945B2 (en) Process for the preparation of 2,5-furan-dicarboxylic acid
CN105669398B (zh) 生产苯甲醛的装置及方法
CN100506766C (zh) 一种2,7-二溴芴的制备方法
CN105037251A (zh) 一种3,5-二甲基吡啶的提纯方法
CN104030972A (zh) 一种吡啶酮的合成方法
CN102399183B (zh) 一种制备吡啶羧酸的方法
Jagadishbabu et al. One pot synthesis of acridine analogues from 1, 2-diols as key reagents
CN103508963A (zh) 一种阿昔莫司的制备方法
TW201439052A (zh) 乙醛之製造方法
JP2010018629A5 (zh)
EP1734029A1 (en) Process for producing aromatic carboxylic acid
TWI565689B (zh) 二氯丙醇的製造方法與環氧氯丙烷的製造方法
CN102952143A (zh) 一种四苯基卟吩的制备方法
CN105753781B (zh) 一种4‑溴甲基喹啉酮的绿色合成方法
CN109503469B (zh) 一种2-乙酰基吡啶的制备方法
CN101648912B (zh) 一种4-硝基-3,5-二甲基吡啶-n-氧化物的连续化制备方法
CN102675196A (zh) 一种利用dctc短蒸残渣制备5,6-二氯烟酸的方法
CN105198890B (zh) 一种四苯基卟吩的生产方法
CN107344904B (zh) 一种钯催化氧化烯烃生成甲基酮的方法
CN109867587A (zh) 一种3氯-1,2-丙二醇的制备方法
CN106187876A (zh) 一种2‑氯烟酸的合成方法
TW201341374A (zh) 環氧丙烷的製造過程
CN104262247B (zh) 一种2,6-二氨基-3,5-二硝基吡啶-1-氧化物的合成方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20180518

Address after: 210047 No. 168 aromatics South Road, chemical industrial park, Liuhe District, Nanjing, Jiangsu

Co-patentee after: Nanjing Redsun Co., Ltd.

Patentee after: Nanjing Red Sun Biological Chemical Co., Ltd.

Address before: 210047 No. 168 aromatics South Road, chemical industrial park, Liuhe District, Nanjing, Jiangsu

Patentee before: Nanjing Red Sun Biological Chemical Co., Ltd.